Screening with X-rays

In the October Nature Biotechnology, Nienaber et al. demonstrate that drug or inhibitor leads can be identified by high throughput X-ray crystallography (Nat. Biotech. 2000, 18:1105-1108). Pre-formed protein crystals are soaked in solvents containing mixtures of 100 compounds before the crystals are examined by X-ray crystallography. Nienaber et al. look for changes in the electron-density map caused by ligand binding.

By | October 10, 2000

In the October Nature Biotechnology, Nienaber et al. demonstrate that drug or inhibitor leads can be identified by high throughput X-ray crystallography (Nat. Biotech. 2000, 18:1105-1108). Pre-formed protein crystals are soaked in solvents containing mixtures of 100 compounds before the crystals are examined by X-ray crystallography. Nienaber et al. look for changes in the electron-density map caused by ligand binding. The compounds in each mixture are chosen to be diverse in shape so that they can be differentiated readily, and the technique allows the site and orientation of binding to be identified. Nienaber et al. use this method to screen thousands of compounds per day in a successful search for a high affinity inhibitor of the anti-cancer target urokinase.

Popular Now

  1. Gut Microbes Linked to Neurodegenerative Disease
  2. Opinion: WHO’s Silence on Cannabis
  3. Top 10 Innovations 2016
    Features Top 10 Innovations 2016

    This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.

  4. Infant Microbiome: Vaginal Delivery Versus C-Section
Rockland